Abstract:Uveal melanoma (UM) is the most common malignant intraocular tumour in the adult population. It is a rare cancer with an incidence of nearly five cases per million inhabitants per year, which develops from the uncontrolled proliferation of melanocytes in the choroid (≈90%), ciliary body (≈6%) or iris (≈4%). Patients initially present either with symptoms like blurred vision or photopsia, or without symptoms, with the tumour being detected in routine eye exams. Over the course of the disease, metastases, which are initially dormant, develop in nearly 50% of patients, preferentially in the liver. Despite decades of intensive research, the only approach proven to mildly control disease spread are early treatments directed to ablate liver metastases, such as surgical excision or chemoembolization. However, most patients have a limited life expectancy once metastases are detected, since there are limited therapeutic approaches for the metastatic disease, including immunotherapy, which unlike in cutaneous melanoma, has been mostly ineffective for UM patients. Therefore, in order to offer the best care possible to these patients, there is an urgent need to find robust models that can accurately predict the prognosis of UM, as well as therapeutic strategies that effectively block and/or limit the spread of the metastatic disease. Here, we initially summarized the current knowledge about UM by compiling the most relevant epidemiological, clinical, pathological and molecular data. Then, we revisited the most important prognostic factors currently used for the evaluation and follow-up of primary UM cases. Afterwards, we addressed emerging prognostic biomarkers in UM, by comprehensively reviewing gene signatures, immunohistochemistry-based markers and proteomic markers resulting from research studies conducted over the past three years. Finally, we discussed the current hurdles in the field and anticipated the future challenges and novel avenues of research in UM.

[Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches]

Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches

Uveal melanoma: molecular-genetic mechanisms of arising and the therapeutic approaches

Uveal Melanoma: Progress in Molecular Biology and Therapeutics.

Uveal melanoma: laboratory advances and new frontiers in patient care

Recent Advances in Molecular and Genetic Research on Uveal Melanoma

Development of New Therapeutic Options for the Treatment of Uveal Melanoma

Current molecular and clinical insights into uveal melanoma (Review)

Genetic Features of Uveal Melanoma

Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations

Pathological and Molecular Diagnosis of Uveal Melanoma

Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma

Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions

Uveal melanoma: Recent advances in immunotherapy

Identifying biomarkers and novel therapeutic targets in uveal melanoma

Recent Advances and Challenges in Uveal Melanoma Immunotherapy

Emerging insights into the molecular pathogenesis of uveal melanoma

Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing.

Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives

From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma

The Prognostic Landscape of Adaptive Immune Resistance Signatures and Infiltrating Immune Cells in the Tumor Microenvironment of Uveal Melanoma.